Abiopharma

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

IMUNON Announces Reverse Stock Split